Back HIV/AIDS HIV/AIDS Topics HIV Treatment IAS 2017: TAG Releases Annual HIV, Hepatitis C, and TB Pipeline Report

IAS 2017: TAG Releases Annual HIV, Hepatitis C, and TB Pipeline Report

alt

On July 18 the Treatment Action Group (TAG) announced the launch of its latest overview of investigational therapies for HIV, hepatitis C virus (HCV), and tuberculosis (TB).

The Pipeline Report: Drugs, Diagnostics, Vaccines, Preventive Technologies, Research Toward a Cure, and Immune-Based and Gene Therapies in Developmentwas released ahead of the 9th International AIDS Society (IAS) Conference on HIV Science, taking place July 23-26 in Paris.

This year’s report acknowledges some critical challenges, including "unstable political environments that threaten scientific progress and the translation of research into health and survival for people around the world," according to a TAG press release.

"The tremendous gains of the past 3 decades and our ability to ensure that all those who can benefit from them receive the prevention, treatment, support, information, and care that they need are under threat by the retrenchment and austerity imposed by Western governments on their own people and the flatlining of investment in research and global HIV and TB prevention and treatment programs," TAG executive director Mark Harrington wrote in the report’s executive summary.
  
The report notes that highly effective and well-tolerated new interferon-free therapies for hepatitis C are unavailable to many people who need them, and inadequate harm reduction and addiction treatment services threaten to increase HCV rates among people who inject drugs -- including young people -- in the context of a growing opioid epidemic in the U.S.

Emerging options for HIV prevention and treatment are also out of reach for many, in part due to high drug costs.

"The HIV pipelines are robust with potentially safe and efficacious treatment and prevention candidates for those who need them most," said Tim Horn, TAG's deputy executive director of HIV and HCV programs.

"At TAG, we firmly believe we can end these three epidemics," the press release concludes. "That requires a commitment to research and the implementation of evidence-based tools to guarantee that people in need are able to access quality health care."

7/21/17

Source

Treatment Action Group. TAG’s Annual Pipeline Report:
Promising New HIV, TB & HCV Drugs and Diagnostics
But Political Will Slows Progress. Press release. July 18, 2017.